磁共振成像与计算机断层扫描对比剂的最新进展与未来展望
本文综述近5–8年CT与MRI对比剂的临床进展、疗效与安全性:CT方面回顾低渗与等渗碘对比剂对肾和甲状腺功能的影响,关注对比增强乳腺摄影并简要展望光子计数CT;MRI方面更新一般安全性、肾源性系统性纤维化及脑内钆沉积,重点介绍两种新型高弛豫率钆对比剂钆匹醇与处于临床后期开发阶段的钆夸曲兰,并描述靶向钆对比剂、超顺磁性氧化铁颗粒、锰基对比剂及新兴的类淋巴系统成像。
要点
- CT:低渗与等渗碘对比剂总体安全性及对肾、甲状腺功能的影响是综述重点。
- MRI:钆匹醇与钆夸曲兰为两种新型高弛豫率钆对比剂,后者处于临床后期开发。
- 新兴方向包括靶向钆对比剂、超顺磁性氧化铁颗粒、锰基对比剂与类淋巴系统成像。
核心结论
- 综述系统评估CT与MRI对比剂近5–8年的临床进展、疗效与安全性,并展望未来方向。
研究设计与样本
- 综述纳入近5–8年的新临床进展,从临床疗效与安全性两方面进行述评。
诊断标准与关键数值
- CT部分回顾低渗与等渗碘对比剂的总体安全性及其对肾功能和甲状腺功能的影响。
- MRI部分更新一般安全性、肾源性系统性纤维化及脑内钆沉积的相关内容。
- 重点介绍钆匹醇与钆夸曲兰两种新型高弛豫率钆对比剂,后者处于临床后期开发阶段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This review provides a comprehensive analysis of recent advancements in computed tomography (CT) and magnetic resonance imaging (MRI) contrast media, offering a critical evaluation of current trends and exploring future directions in the field. New clinical developments within the last 5-8 years are considered as well as clinical efficacy and safety aspects.For CT, the general safety of low- and iso-osmolar iodinated contrast agents and their effect on renal and thyroid function are reviewed. Special attention is given to contrast-enhanced mammography and a short outlook to photon-counting CT is provided.For MRI, a brief update on general safety, nephrogenic systemic fibrosis and the presence of gadolinium in the brain is given. The 2 new high-relaxivity gadolinium-based contrast agents, gadopiclenol and gadoquatrane (in late-stage clinical development), are highlighted.The review also describes targeted gadolinium-based contrast agents, superparamagnetic iron oxide particles, and developments of manganese-based contrast agents. It also introduces the emerging field of glymphatic imaging.
引用
- Frenzel T, Wels T, Pietsch H, et al. Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media. Invest Radiol. 2026. PMID: 40163898. doi:10.1097/RLI.0000000000001180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。